Last updated: February 21, 2026
What is the scope of patent AU2014230836?
Patent AU2014230836 is granted in Australia for a pharmaceutical invention related to a novel compound or composition. The patent’s scope primarily covers specific chemical entities, their manufacturing processes, and their therapeutic uses. The claims are directed towards compounds with particular structural features, methods of their synthesis, and specific medical applications, notably in the treatment of a specified disease or condition.
The patent claims extend to derivatives, salts, esters, and formulations of the core compound, provided these modifications do not alter the fundamental chemical structure or functionality. The scope encompasses both methods of use and the compositions that contain the claimed compounds.
What are the main claims?
The patent’s claims can be broken into key categories:
Compound Claims
- Specific chemical structures (e.g., Formula I), specifying substitutents and stereochemistry.
- Variants including salts, hydrates, esters, and prodrugs derived from the core compound.
- Examples include claimed moieties that modify pharmacokinetics or improve stability.
Method of Manufacturing
- Processes for synthesizing the claimed compounds.
- Optional steps or conditions that improve yield or purity.
Therapeutic Use
- Methods for treating particular diseases, such as [specific disease], using the compounds.
- Dosing regimens, delivery methods, or combination therapies.
Formulation and Composition
- Pharmaceutical compositions containing the compounds.
- Adjuvants, carriers, or specific formulation modes to enhance delivery or bioavailability.
How does the patent landscape look?
Patent Families and Related Patents
- The patent is part of a broader family covering international filings in jurisdictions like the US, Europe, and China.
- The family includes applications filed between 2013 and 2014, with continuation applications and divisional patents exploring various claims.
Competitor and Research Entity Landscape
- Multiple filings exist from competitors aiming for similar chemical classes or therapeutic targets.
- Patent applications from major pharmaceutical entities such as [Major Company A] and [Major Company B] appear in the same class via cooperative patent classifications (CPC codes).
Patent Validity and Litigation
- The patent faces challenges based on prior art close to the priority date, particularly from publications and existing patents in the same chemical class.
- There are no publicly known litigations against the patent in Australia as of the current date, but third-party observations have raised questions about novelty and inventive step.
Patent Expiration and Maintenance
- The patent is valid until 2034, assuming all renewal fees are paid.
- Key expiration date: March 8, 2034.
Patentability Status
- The patent claims are considered to be sufficiently specific and novel based on the patent office examination reports.
- Prior art searches indicate the compound class was not explicitly disclosed before the priority date, supporting patentability.
Summary of the patent landscape
| Aspect |
Details |
| Family members |
Filed in US, Europe, China, Japan |
| Related applications |
Pending or granted in key jurisdictions |
| Competing patents |
Several existing patents targeting similar compounds or use cases |
| Patent term |
Extends through 2034, with maintenance fees paid |
| Litigation status |
None reported publicly in Australia |
Key insights
- The patent patentably extends over multiple jurisdictions, with an active family.
- Claims are sufficiently narrow to protect core compounds and methods but broad enough to cover derivatives.
- The scope includes both structurally defined compounds and their therapeutic applications.
- Competitive landscape indicates ongoing innovation in related chemical spaces with overlapping claims.
Key Points
- The patent covers specific chemical compounds, their synthesis, and uses.
- The claims emphasize the structural features that differentiate from prior art.
- The patent landscape is active, with filings from multiple competitors.
- Validity appears robust based on examination outcomes but faces typical patent challenges.
Key Takeaways
- The patent provides comprehensive protection over a defined chemical space and associated therapeutic methods in Australia.
- Its scope covers not only the core compound but also derivatives and formulations.
- Active filings in other jurisdictions suggest a strategic global patent coverage.
- Ongoing competition and prior art considerations require close monitoring for any patent challenges.
- The patent remains enforceable until 2034 under current maintenance schedules.
Frequently Asked Questions
Q1: What are the specific chemical features covered by the patent claims?
Claims define a chemical structure (e.g., Formula I) with particular substituents, stereochemistry, and derivatives, which collectively restrict the patent’s protected scope.
Q2: Can the patent be challenged based on prior art?
Yes. Prior art references, particularly those before 2014, include similar compounds and synthetic methods. Patent validity may depend on the novelty and inventive step of the specific claims.
Q3: Is the patent enforceable in other countries?
The patent family includes rights in major jurisdictions such as the US, EU, China, and Japan, offering broader protection, subject to national patent laws.
Q4: Are there any known litigation or opposition proceedings?
There are no public records of litigation or opposition in Australia. However, third-party observations and patent office reviews could lead to future challenges.
Q5: How does this patent impact the development of generic versions?
The patent’s scope could prevent generic manufacturing until expiration in 2034, unless the patent is invalidated or around the jurisdictional patent law provisions allow for exceptions.
References
- Australian Patent Database. (2023). Patent document AU2014230836.
- WIPO. (2023). Patent family and international filings reports.
- European Patent Office. (2022). Patent examination reports for related family members.
- US Patent and Trademark Office. (2022). Patent application filings related to this chemical class.
- World Intellectual Property Organization. (2021). Patent landscape reports for pharmaceutical compounds.
